Literature DB >> 31408724

mTOR: Role in cancer, metastasis and drug resistance.

Avaniyapuram Kannan Murugan1.   

Abstract

Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that gets inputs from the amino acids, nutrients, growth factor, and environmental cues to regulate varieties of fundamental cellular processes which include protein synthesis, growth, metabolism, aging, regeneration, autophagy, etc. The mTOR is frequently deregulated in human cancer and activating somatic mutations of mTOR were recently identified in several types of human cancer and hence mTOR is therapeutically targeted. mTOR inhibitors were commonly used as immunosuppressors and currently, it is approved for the treatment of human malignancies. This review briefly focuses on the structure and biological functions of mTOR. It extensively discusses the genetic deregulation of mTOR including amplifications and somatic mutations, mTOR-mediated cell growth promoting signaling, therapeutic targeting of mTOR and the mechanisms of resistance, the role of mTOR in precision medicine and other recent advances in further understanding the role of mTOR in cancer.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Inhibitors; Metastasis; Molecular target; Mutation; Oncogene; Precision medicine; Resistance; mTOR

Mesh:

Substances:

Year:  2019        PMID: 31408724     DOI: 10.1016/j.semcancer.2019.07.003

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  83 in total

1.  Circ_0028007 Aggravates the Malignancy of Nasopharyngeal Carcinoma by Regulating miR-656-3p/ELF2 Axis.

Authors:  Xiaojun Ma; Yan Li
Journal:  Biochem Genet       Date:  2022-03-03       Impact factor: 1.890

2.  Integrative multiplatform-based molecular profiling of human colorectal cancer reveals proteogenomic alterations underlying mitochondrial inactivation.

Authors:  Wei Zhang; Donge Tang; Liewen Lin; Tingting Fan; Ligang Xia; Wanxia Cai; Weier Dai; Chang Zou; Lianghong Yin; Yong Xu; Yong Dai
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

3.  A preclinical report of a cobimetinib-inspired novel anticancer small-molecule scaffold of isoflavones, NSC777213, for targeting PI3K/AKT/mTOR/MEK in multiple cancers.

Authors:  Bashir Lawal; Wen-Cheng Lo; Ntlotlang Mokgautsi; Maryam Rachmawati Sumitra; Harshita Khedkar; Alexander Th Wu; Hsu-Shan Huang
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

4.  Integrated analysis identifies a novel lncRNA prognostic signature associated with aerobic glycolysis and hub pathways in breast cancer.

Authors:  Zheng Li; Juan Zheng; Yang Feng; Yaming Li; Yiran Liang; Ying Liu; Xiaolong Wang; Qifeng Yang
Journal:  Cancer Med       Date:  2021-09-27       Impact factor: 4.452

5.  Expression of LAT1 and 4F2hc in Gastroenteropancreatic Neuroendocrine Neoplasms.

Authors:  Yosuke Horita; Kyoichi Kaira; Tomonori Kawasaki; Yoshiaki Mihara; Shinichi Sakuramoto; Shigeki Yamaguchi; Kojun Okamoto; Shomei Ryozawa; Yoshikatsu Kanai; Masanori Yasuda; Tetsuya Hamaguchi
Journal:  In Vivo       Date:  2021 Jul-Aug       Impact factor: 2.155

6.  Comprehensive evaluation of microRNA-10b in digestive system cancers reveals prognostic implication and signaling pathways associated with tumor progression.

Authors:  Yi Shen; Xiaolei Dai; Haibo Chen; Shuwei Zhai; Qiliang Peng; Shang Cai; Yaqun Zhu; Jian Huan; Yuntian Shen
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

7.  mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer.

Authors:  Ling Tian; Congcong Chen; Yanguan Guo; Fan Zhang; Jinye Mi; Qi Feng; Shengbin Lin; Naite Xi; Jiaxin Tian; Li Yu; Yan Chen; Mingrong Cao; Caiyong Lai; Jun Fan; Yongchang Zhang; Guo Chen
Journal:  Neoplasia       Date:  2021-06-11       Impact factor: 5.715

8.  Development and Validation of a Robust Ferroptosis-Related Prognostic Signature in Lung Adenocarcinoma.

Authors:  Anran Zhang; Jinpo Yang; Chao Ma; Feng Li; Huan Luo
Journal:  Front Cell Dev Biol       Date:  2021-06-24

9.  Genomic and Transcriptome Analysis to Identify the Role of the mTOR Pathway in Kidney Renal Clear Cell Carcinoma and Its Potential Therapeutic Significance.

Authors:  Xiangyu Che; Xiaochen Qi; Yingkun Xu; Qifei Wang; Guangzhen Wu
Journal:  Oxid Med Cell Longev       Date:  2021-06-07       Impact factor: 6.543

10.  The polyphenol/saponin-rich Rhus tripartita extract has an apoptotic effect on THP-1 cells through the PI3K/AKT/mTOR signaling pathway.

Authors:  Hajer Tlili; Anca Macovei; Daniela Buonocore; Manuela Lanzafame; Hanen Najjaa; Anita Lombardi; Andrea Pagano; Maurizia Dossena; Manuela Verri; Abdelkarim Ben Arfa; Mohamed Neffati; Enrico Doria
Journal:  BMC Complement Med Ther       Date:  2021-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.